AAT-AD/PD 2018 - Abstract Topics


Abstract Submission is now open,  please visit Abstract Submission & Guidelines.

To receive updates on abstract submission, please enter your email address below.

Keep Me Updated




β-Amyloid Diseases
Alzheimer's Disease (AD), Prodromal AD, Cerebral Amyloid Angiopathy (CAA), Down Syndrome (DS) & Mild Cognitive Impairment (MCI)
A1Disease Mechanisms,  PathophysiologyA1.aAbeta aggregation, protein misfolding
A1.bcell to cell transmission, spreading of pathology, prion-like
A1.dvasculature, microbleeds, hypertension, angiogenesis
A2Therapeutic Targets, Mechanisms for TreatmentA2.aAbeta, truncated & pGlu-Abeta
A2.csecretases, proteases
A2.dneurotransmitters & receptor-based
A2.eApoE & lipoprotein-based
A2.gneurotrophic, synaptic plasticity, repair, regenerative medicine
A3Drug Development,  Clinical Trials and Trial DesignA3.aimmunotherapy
A3.camyloid clearance
A3.dsecretase inhibitors & modulators
A3.eaggregation inhibitors
A3.fneurotransmitter-based modulators
A3.greceptor ligands
A3.hmedicinal chemistry approaches, drug repurposing, translational strategies
A3.iprecision medicine or personalized medicine
A3.jregulatory aspects
A3.kmultidomain prevention studies 
A4Imaging and Biomarkers for Clinical Inclusion & Outcome MeasuresA4.astructural MRI, MR spectroscopy
A4.bfunctional MRI
A4.cPET - amyloid
A4.dPET - glucose
A4.ePET - other
A4.fmultimodal imaging
A4.gCSF, blood, body fluid biomarkers
A4.hcognitive, psychometric & behavioral tests
A5Epidemiology and Genetics in Clinical TrialsA5.awhole genome sequencing
A5.bdisease-causing mutations
A5.cGWAS, genetic associations, susceptibility & protective genes
A5.dmetabolic and cardiovascular
A5.esex and gender-specific   genotypes
A6Cell, Molecular & Systems BiologyA6.aAPP, APLP, Abeta
A6.cgrowth factors, synaptic plasticity
A6.dGCPR, nicotinic, sigma-1 & other receptors
A6.e microbiota,  immune system,  inflammation
  A7.atranslational aspects
AD, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD), Pick's Disease & Chronic Traumatic Encephalopathy 
B1Disease Mechanisms,  PathophysiologyB1.atau aggregation, phophorylation, acetylation & modifications
B1.bcell to cell transmission, spreading of pathology, prion-like
B1.dmetabolism, insulin
B1.eautophagy,  apoptosis, cell death
B1.fprotein misfolding, chaperones
B2Therapeutic Targets, Mechanisms for TreatmentB2.atau, phosphorylation, truncation
B2.ckinases, phosphatases, other enzymes
B2.dneurotransmitters & receptor-based
B2.fneurotrophic, synaptic plasticity, repair
B2.gprotein aggregation, NFT, misfolding, chaperones
B2.hprecision medicine or personalized medicine
B3Drug Development,  Clinical Trials and Trial DesignB3.aimmunotherapy
B3.dclearance of pathologial tau
B3.eprecision medicine or personalized medicine
B3.fregulatory aspects
B4Imaging and Biomarkers for Clinical Inclusion & Outcome MeasuresB4.astructural MRI, MR spectroscopy
B4.bfunctional MRI
B4.cPET - tau
B4.dPET - glucose
B4.ePET - other
B4.fmultimodal imaging
B4.gCSF, blood, body fluid biomarkers
B4.hcognitive, psychometric & behavioral tests
B5 Epidemiology and Genetics in Clinical TrialsB5.awhole genome sequencing
B5.bdisease-causing mutations
B5.cGWAS, genetic associations, susceptibility & protective genes
B5.eenvironmental risk factors
B5.fmetabolic, cardiovascular, inflammation
B6Cell, Molecular &  Systems BiologyB6.atau, tau isoforms
B6.bkinases, phosphatases
B6.dgrowth factors, synaptic plasticity
B6.eGCPR, nicotinic, sigma-1, other receptors
B6.fnetwork biology, connectome, protein-protein interations
B6.gmetabolomics, transcriptomics, lipidomics, proteomics
B4.h microbiota,  immune system,  inflammation
  B7.3translational aspects
Parkinson's Disease (PD), PD Dementia, Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), Olivopontocerebellar Atrophy (OPCA)
C1Disease Mechanisms ,  PathophysiologyC1.aα-synuclein aggregation
C1.bLRKK2, parkin, PINK1, DJ-1
C1.ccell to cell transmission, spreading of pathology, prion-like
C1.dautophagy, apoptosis, cell death, lysosomes, ubiquitin, proteasome
C2Therapeutic Targets, Mechanisms for TreatmentC2.aα-synuclein
C2.ddopamine, neurotransmitters
C2.ecell transplantation and stem cells
C2.fdeep brain stimulation
C2.ganti-inflammatory, anti-oxidant
C2.hprotein aggregation, misfolding, chaperones
C3Drug Development,  Clinical Trials and Trial DesignC3.aimmunotherapy
C3.bvitamins, antioxidants, neuroprotective compounds
C3.cneurotransmitter- and receptor based modulators
C3.ddeep brain stimulation
C3.eaggregation inhibitors
C3.fenzyme modulators
C3.gmedicinal chemistry approaches, drug repurposing, translational strategies
C3.hnon-pharmacological interventions, neurosurgery
C4Imaging and Biomarkers for Clinical Inclusion & Outcome MeasuresC4.astructural MRI, MR spectroscopy
C4.bfunctional MRI
C4.emultimodal imaging
C4.fCSF, blood, body fluid biomarkers
C4.gcognitive, psychometric, behavioral and motor tests
C5Epidemiology and Genetics in Clinical TrialsC5.awhole genome sequencing
C5.bdisease-causing mutations
C5.cGWAS, genetic associations, susceptibility & protective genes
C5.eenvironmental risk factors
C6Cell, Molecular &  Systems BiologyC6.aα-synuclein
C6.bLRKK2, parkin, PINK1, DJ-1
C6.dGCPR, dopamine & other receptors
C6.enetwork biology, connectome, protein-protein interations
C6.f microbiota,  immune system,  inflammation
   C7.atranslational aspects
TDP-43- and C9orf72-Related Diseases Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), ALS-FTD Spectrum Diseases1Disease Mechanisms,  Pathophysiology
Vascular Dementia, Multi-Infarct Dementia (MID), White Matter Disease & Stroke 2Therapeutic Targets, Mechanisms for Treatment
3Drug Development,  Clinical Trials and Trial Design
Lysosomal and Storage Diseases,Gaucher, Niemann Pick etc.4Imaging and Biomarkers for Clinical Inclusion & Outcome Measures
Psychiatric and Epileptic Symptoms in Neurodegenerative Diseases5Epidemiology and Genetics in Clinical Trials
Patient Care and SupportK1Dementia & Cognitive DysfunctionK1.acaregiver support
K1.bmobile applications, social networks
K1.ccognitive training
K1.esupport devices & monitoring
K1.fquality of life, superagers 
K1.gfunctional foods
K1.hbehavioral & psychiatric symptoms 
K1.ifall prevention & patient protection
K1.jmultidomain prevention studies 
K2Movement DisordersK2.acaregiver support
K2.bmobile applications, social networks
K2.cmotor coordination & exercise
K2.dsupport devices & monitoring
K2.efunctional foods
K2.fquality of life, superagers 
K2.gfall prevention & patient protection
K2.hbehavioral & psychiatric symptoms 

For more information and to submit your abstract, please visit Abstract Submission & Guidelines.